When is Equity More than Just Financing? Evidence from Strategic Alliances
47 Pages Posted: 1 Oct 2012 Last revised: 22 Jan 2013
Date Written: September 30, 2012
Abstract
A strategic alliance is a hybrid organizational form that is between an arms length contract and a full-fledged merger between firms. In some alliances firms take a minority equity stake in the partner firm. We refer to these as equity alliances. Using data on 759 alliances, we examine the motivation for the use of equity in alliances. We study whether equity is intended to strengthen the contractual performance of the alliance or whether it is primarily a means of financing for the capital constrained partner in the alliance. Consistent with the incomplete contracts theory, we find that equity is more likely to be used in alliances where the exact nature and the sharing of the output is ambiguous. We also find that equity is more likely to be used when the difference in bargaining powers between the partners is higher, such as when the partners differ significantly in size, market power, and growth opportunities. Finally, we find that equity alliances are especially likely when the smaller partner (which is almost always the partner selling equity) is high growth but is capital constrained. Thus, equity from alliance partners is a viable alternative source of capital for such firms. Consistent with the view that equity usage mitigates contracting costs and capital constraints, the market reaction to equity alliances is significantly higher compared to other alliances. Overall, the evidence suggests that the market views equity investments in alliances as more valuable than toeholds taken by potential acquirers without a product market relationship.
Suggested Citation: Suggested Citation
Do you have a job opening that you would like to promote on SSRN?
Recommended Papers
-
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
By Ilan Guedj and David S. Scharfstein
-
By Ilan Guedj and David S. Scharfstein
-
Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
By Sean Nicholson, Patricia M. Danzon, ...
-
Financial Contracting in Biotech Strategic Alliances
By David T. Robinson and Toby Stuart
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
By Patricia M. Danzon, Sean Nicholson, ...